Table 3.

Association of rs2736098 (A) on 5p15.33 to basal cell carcinoma, cancers of the lung, bladder, prostate and cervix

Study population	Number		Frequency		OR	95% CI	P value
	Cases	Controls	Cases	Controls
Basal cell carcinoma
Iceland	1,600	3,667	0.327	0.272	1.30	1.18–1.43	1.4 ×10−7
Eastern Europe	496	491	0.249	0.264	0.93	0.77–1.12	0.45
All combineda	2,096	4,158	0.288	0.268	1.21	1.11–1.32	1.3×10−5
Lung cancer
Iceland	687	3,667	0.306	0.272	1.18	1.03–1.35	0.014
The Netherlands	525	1,740	0.326	0.286	1.21	1.04–1.41	0.014
Spain	365	1,384	0.271	0.229	1.25	1.04–1.51	0.019
All combineda	1,577	6,791	0.301	0.262	1.20	1.10–1.31	3.2×10−5
Bladder cancer
Iceland	460	3,667	0.283	0.272	1.05	0.90–1.22	0.53
The Netherlands	1,212	1,740	0.308	0.286	1.11	0.90–1.24	0.066
UK	677	486	0.313	0.270	1.24	1.03–1.49	0.023
Italy-Torino	322	375	0.278	0.249	1.16	0.91–1.48	0.23
Italy-Brescia	99	132	0.272	0.227	1.28	0.83–1.97	0.26
Belgium	188	365	0.293	0.271	1.11	0.84–1.46	0.46
Eastern Europe	206	491	0.323	0.264	1.33	1.03–1.71	0.026
Sweden	332	436	0.294	0.227	1.41	1.12–1.77	0.0031
Spain	173	1,384	0.249	0.229	1.11	0.86–1.43	0.42
All combineda	3,669	9,076	0.290	0.255	1.16	1.08–1.23	1.3×10−4
Prostate cancer
Iceland	1,640	3,667	0.290	0.272	1.09	0.99–1.20	0.076
The Netherlands	983	1,740	0.319	0.286	1.17	1.04–1.32	0.0096
Chicago, US	627	679	0.305	0.268	1.20	1.01–1.43	0.039
Spain	449	1,384	0.252	0.229	1.13	0.95–1.34	0.17
All combineda	3,699	7,470	0.291	0.264	1.13	1.06–1.21	1.3 ×10−4
Cervical cancer
Iceland	249	3,667	0.295	0.272	1.12	0.91–1.37	0.28

Shown are the corresponding numbers of cases and controls (N), allelic frequencies of variants, the allelic odds-ratio (OR) with P values based on the multiplicative model.

^aFor the combined study populations, the reported control frequency was the average, unweighted control frequency of the individual populations, while the OR and the P value were estimated using the Mantel-Haenszel model.